MedTrace Logo

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

NCT00958074 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-10-18

Study results available
· View outcomes & findings →

Summary

This phase II trial studies the side effects and how well vorinostat works in treating patients with primary cutaneous T-cell lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

Conditions

  • Cutaneous T-cell Lymphoma Stage I
  • Cutaneous T-cell Lymphoma Stage II
  • Cutaneous T-cell Lymphoma Stage III
  • Cutaneous T-cell Lymphoma Stage IV

Interventions

DRUG

vorinostat

Given PO

OTHER

flow cytometry

correlative study

OTHER

laboratory biomarker analysis

correlative study

Sponsors & Collaborators

Principal Investigators

  • Andrei Shustov · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2013-02-28
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00958074 on ClinicalTrials.gov